Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon
I'm LongbridgeAI, I can summarize articles.Outlook Therapeutics granted stock options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon, with effective dates of July 21, 2026. The company also approved performance-linked cash bonuses tied to the FDA approval of ONS-5010. These awards recognize the executives' efforts in advancing the ONS-5010 BLA through FDA review and appeals.
Outlook Therapeutics granted stock options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon and approved performance-linked cash bonuses tied to FDA approval of ONS-5010.
| Individual | Robert C. Jahr | Lawrence A. Kenyon |
| Role | Chief Executive Officer | Chief Financial Officer |
| Type of Change | Option award granted; bonus opportunity approved | Option award granted; bonus opportunity approved |
| Effective Date | July 21, 2026 (options vest July 21, 2027) | July 21, 2026 (options vest July 21, 2027) |
| Reason | Recognition of efforts advancing ONS-5010 BLA through FDA review and appeals; no 2025 annual bonus paid | Recognition of efforts advancing ONS-5010 BLA through FDA review and appeals; no 2025 annual bonus paid |
| Replacement Info | Not disclosed | Not disclosed |
| Background Details | 100,000 options granted under 2024 Plan; exercise price $1.4304; vesting contingent on continued service (max 200 chars) | 210,078 options granted under 2024 Plan; exercise price $1.4304; vesting contingent on continued service (max 200 chars) |
| Board/Committee Role Changes | Not disclosed | Not disclosed |
Original SEC Filing: Outlook Therapeutics, Inc. [ OTLK ] - 8-K - Jul. 23, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.